CM4620
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- CM4620
- DrugBank Accession Number
- DB16466
- Background
CM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066 (pancreatitis and SIRS), and NCT04661540 (critical COVID-19 pneumonia).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 421.76
Monoisotopic: 421.0441034 - Chemical Formula
- C19H11ClF3N3O3
- Synonyms
- BENZAMIDE, N-(5-(6-CHLORO-2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)-2-PYRAZINYL)-2-FLUORO-6-METHYL-
- N-(5-(6-CHLORO-2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)PYRAZIN-2-YL)-2-FLUORO-6-METHYLBENZAMIDE
- ZEGOCRACTIN
- External IDs
- AK549808
- BCP29536
- CM 4620
- CM-4620
- CM4620
- CRAC inhibitor CM4620
- CS-0022201
- EX-A1898
- GTPL10087
- HY-101942
- orai Ca2+ channel inhibitor CM4620
- orai1 inhibitor CM4620
- SB18686
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
CM4620 is a small molecule inhibitor of calcium release-activated channel. It inhibits calcium entry via the store-operated calcium entry channels (SOCE) and acts as an anti-inflammatory compound by reducing cytokine expression and myeloperoxidase activity.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 564AW1RR37
- CAS number
- 1713240-67-5
- InChI Key
- QQMKTHUGOQDEIL-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H11ClF3N3O3/c1-9-3-2-4-12(21)17(9)18(27)26-16-8-24-13(7-25-16)10-5-14-15(6-11(10)20)29-19(22,23)28-14/h2-8H,1H3,(H,25,26,27)
- IUPAC Name
- N-[5-(6-chloro-2,2-difluoro-2H-1,3-benzodioxol-5-yl)pyrazin-2-yl]-2-fluoro-6-methylbenzamide
- SMILES
- CC1=CC=CC(F)=C1C(=O)NC1=NC=C(N=C1)C1=CC2=C(OC(F)(F)O2)C=C1Cl
References
- General References
- Waldron RT, Chen Y, Pham H, Go A, Su HY, Hu C, Wen L, Husain SZ, Sugar CA, Roos J, Ramos S, Lugea A, Dunn M, Stauderman K, Pandol SJ: The Orai Ca(2+) channel inhibitor CM4620 targets both parenchymal and immune cells to reduce inflammation in experimental acute pancreatitis. J Physiol. 2019 Jun;597(12):3085-3105. doi: 10.1113/JP277856. Epub 2019 May 22. [Article]
- External Link [Link]
- External Links
- ChemSpider
- 58810276
- ChEMBL
- CHEMBL4753998
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Completed Treatment Acute Pancreatitis / Systemic Inflammatory Response Syndrome (SIRS) 1 somestatus stop reason just information to hide 1, 2 Recruiting Treatment Acute Pancreatitis 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 5.53 Chemaxon pKa (Strongest Acidic) 13.34 Chemaxon pKa (Strongest Basic) -0.84 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 73.34 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 96.25 m3·mol-1 Chemaxon Polarizability 38.02 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at January 21, 2021 01:43 / Updated at July 23, 2024 18:02